Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD

References

• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• WorthHForsterKErikssonGNihlenUPetersonSMagnussenHBudesonide added to formoterol contributes to improved exercise tolerance in patients with COPDRespir Med2010104101450145920692140
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• PauwelsRALofdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
   PubMed Web of Science ®Google Scholar
• HollisSJorupCLythgoeDMartenssonGRegnellPEckerwallGRisk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studiesInt J Chron Obstruct Pulmon Dis2017121071108428435240
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• LarssonKJansonCLisspersKCombination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS studyJ Intern Med2013273658459423495860
   PubMed Web of Science ®Google Scholar
• JansonCLarssonKLisspersKHPneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS)BMJ2013346f330623719639
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKRisk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and updateCurr Opin Pulm Med201016211812219926996
   PubMed Web of Science ®Google Scholar
• HalpinDMGrayJEdwardsSJMoraisJSinghDBudesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trialsInt J Clin Pract201165776477421676119
   PubMed Web of Science ®Google Scholar
• SpencerSKarnerCCatesCJEvansDJInhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201112CD007033
   Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00682922972099
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00379424214176
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD01011524615270
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyPRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease2016 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Inhaled_corticosteroids_for_chronic_obstructive_pulmonary_disease/human_referral_prac_000050.jsp&mid=WC0b01ac05805c516fAccessed September 27, 2016
   Google Scholar
• MorjariaJBRigbyAMoriceAHInhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT studyLung201719528128828255905
   PubMed Web of Science ®Google Scholar
• PattonJSBrainJDDaviesLAThe particle has landed–characterizing the fate of inhaled pharamceuticalsJ Aerosol Med Pulm Drug Deliv201023Suppl 2S71S8721133802
   PubMed Web of Science ®Google Scholar
• EdsbackerSWollmerPSelroosOBorgstromLOlssonBIngelfJDo airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?Pulm Pharmacol Ther200821224725817950641
   PubMed Web of Science ®Google Scholar
• JohnsonMPharmacodynamics and pharmacokinetics of inhaled glucocorticoidsJ Allergy Clin Immunol1996971 Pt 21691768568148
   PubMed Web of Science ®Google Scholar
• HaghiMTrainiDPostmaDSBebawyMYoungPMFluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhalerRespirology20131881197120123796052
   PubMed Web of Science ®Google Scholar
• BurMRothen-RutishauserBHuwerHLehrCMA novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulationsEur J Pharm Biopharm200972235035718771729
   PubMed Web of Science ®Google Scholar
• HeinSBurMSchaeferUFLehrCMA new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulationsEur J Pharm Biopharm201177113213820951200
   PubMed Web of Science ®Google Scholar
• HaghiMHittingerMZengQMono- and cocultures of bronchial and alveolar epithelial cells respond differently to proinflammatory stimuli and their modulation by salbutamol and budesonideMol Pharm20151282625263226147243
   PubMed Web of Science ®Google Scholar
• van den BrinkKIBoorsmaMStaal-van den BrekelAJEdsbackerSWoutersEFThorssonLEvidence of the in vivo esterification of budesonide in human airwaysBr J Clin Pharmacol2008661273518384442
   PubMed Web of Science ®Google Scholar
• DalbyCPolanowskiTLarssonTBorgstromLEdsbackerSHarrisonTWThe bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trialRespir Res20091010419878590
   PubMed Web of Science ®Google Scholar
• ThorssonLEdsbackerSKallenALofdahlCGPharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via TurbuhalerBr J Clin Pharmacol200152552953811736861
   PubMed Web of Science ®Google Scholar
• AllenABareillePJRousellVMFluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionateClin Pharmacokinet2013521374223184737
   PubMed Web of Science ®Google Scholar
• Miller-LarssonAMattssonHHjertbergEDahlbackMTunekABrattsandRReversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissueDrug Metab Dispos19982676236309660844
   PubMed Web of Science ®Google Scholar
• BrattsandRMiller-LarssonAThe role of intracellular esterification in budesonide once-daily dosing and airway selectivityClin Ther200325Suppl CC28C4114642802
   PubMed Web of Science ®Google Scholar
• EkALarssonKSiljerudSPalmbergLFluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophagesAllergy199954769169910442524
   PubMed Web of Science ®Google Scholar
• RayKPFarrowSDalyMTalabotFSearleNInduction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoidsBiochem J1997328Pt 27077159371735
   PubMed Web of Science ®Google Scholar
• AtsutaJPlittJBochnerBSSchleimerRPInhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoidsAm J Respir Cell Mol Biol199920464365010100995
   PubMed Web of Science ®Google Scholar
• RossiosCToYToMLong-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cellsEur J Pharmacol2011670124425121920359
   PubMed Web of Science ®Google Scholar
• SalterMBiggadikeKMatthewsJLPharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory diseaseAm J Physiol Lung Cell Mol Physiol20072933L660L66717575011
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHA systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPDPulm Pharmacol Ther2017421627864038
   PubMed Web of Science ®Google Scholar
• AnnaneDCorticosteroids and pneumonia: time to change practiceLancet201538599771484148525608755
   PubMed Web of Science ®Google Scholar
• BlumCANigroNBrielMAdjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trialLancet201538599771511151825608756
   PubMed Web of Science ®Google Scholar
• TorresASibilaOFerrerMEffect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trialJAMA2015313767768625688779
   PubMed Web of Science ®Google Scholar
• SiemieniukRAMeadeMOAlonso-CoelloPCorticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysisAnn Intern Med2015163751952826258555
   PubMed Web of Science ®Google Scholar
• SethiSMaloneyJGroveLWronaCBerensonCSAirway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2006173999199816474030
   PubMed Web of Science ®Google Scholar
• SethiSMurphyTFInfection in the pathogenesis and course of chronic obstructive pulmonary diseaseN Engl J Med2008359222355236519038881
   PubMed Web of Science ®Google Scholar
• GarchaDSThurstonSJPatelARChanges in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPDThorax201267121075108022863758
   PubMed Web of Science ®Google Scholar
• HuangYJSethiSMurphyTNariyaSBousheyHALynchSVAirway microbiome dynamics in exacerbations of chronic obstructive pulmonary diseaseJ Clin Microbiol20145282813282324850358
   PubMed Web of Science ®Google Scholar
• PragmanAAKimHBReillyCSWendtCIsaacsonREThe lung microbiome in moderate and severe chronic obstructive pulmonary diseasePLoS One2012710e4730523071781
   PubMed Web of Science ®Google Scholar
• HajishengallisGDarveauRPCurtisMAThe keystone-pathogen hypothesisNat Rev Microbiol2012101071772522941505
   PubMed Web of Science ®Google Scholar
• HeijinkIHJonkerMRde VriesMBudesonide and fluticasone propionate differentially affect the airway epithelial barrierRespir Res201617226739349
   PubMed Web of Science ®Google Scholar
• HeijinkIJonkerMPostmaDVan den BergeMDifferential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epitheliumEur Respir J201546Suppl 59A2558
   Google Scholar
• ProvostKASmithMMiller-LarssonAGudleskiGDSethiSBacterial regulation of pathogen recognition receptors in macrophages in COPD are differentially modified by budesonide and fluticasone propionate ex vivoAm J Respir Crit Care Med2016193A6335
   Web of Science ®Google Scholar
• JoshiTJohnsonMNewtonRGiembyczMAn analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeuticsBr J Pharmacol20151721360137825393397
   PubMed Web of Science ®Google Scholar
• DonnellyLEBarnesPJDefective phagocytosis in airways diseaseChest20121411055106222474147
   PubMed Web of Science ®Google Scholar
• BerensonCSGarlippMAGroveLJMaloneyJSethiSImpaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary diseaseJ Infect Dis2006194101375138417054066
   PubMed Web of Science ®Google Scholar
• TaylorAEFinney-HaywardTKQuintJKDefective macrophage phagocytosis of bacteria in COPDEur Respir J20103551039104719897561
   PubMed Web of Science ®Google Scholar
• EdsbäckerSBrattsandRBudesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available dataAnn Allergy Asthma Immunol200288660961612086369
   PubMed Web of Science ®Google Scholar